Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-03758309. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 known ✓ | O96013 | 19/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-03758309 SCHEMBL16101450 | 1.00 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| Pf-03758309 SCHEMBL29929908 | 0.99 | PAK4 (0.99) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1369035 | 0.92 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL24513386 | 0.89 | PAK4 (0.81) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1369668 | 0.89 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1942571 | 0.88 | PAK4 (0.80) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1942859 | 0.87 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL1942862 | 0.87 | PAK4 (1.00) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL22164721 | 0.84 | PAK4 (0.72) | PAK4CDK7CCNHMNAT1PLK4 | |
| SCHEMBL22164724 | 0.84 | PAK4 (0.72) | PAK4CDK7CCNHMNAT1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-12360118-B2 | Method for protein kinase activity ranking | KINOMICA LIMITED (GB) | 2025-07-15 | — | — | US | claimed |
| WO-2025096405-A1 | METHODS OF TREATING BLOOD CANCERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250116671-A1 | Kinase Activity In Tumors | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-10 | — | — | US | claimed |
| US-20250041294-A1 | Synergistic compositions for use in the treatment of cancer | SARTAR THERAPEUTICS OY (FI) | 2025-02-06 | — | — | US | claimed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | claimed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| CN-116287093-A | Screening method of cell-embedded death agonist or antagonist and application thereof | 无量光生物科技(鹤山市)有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | claimed |
| CN-115927524-A | Preparation process of compound composition of multiple traditional Chinese medicine active components for treating tumors | 麒麟(山东)医药科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | claimed |
| CN-115192582-A | Application of PAK4 inhibitor in preparation of drugs for targeted inhibition of STAT3 and NF kappa B signal pathways | 麒麟(山东)医药科技有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20150359815-A1 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-12-17 | — | — | US | claimed |
| WO-2014150790-A1 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-09-25 | — | — | WO | claimed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | PAK4 3881/4885CDK7 648/4885CCNH 1547/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885CDK7 228/4885CCNH 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.